BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Main 20 Gaming Control center Ever - 2Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- 3UB professor shares his experience on almost becoming an astronaut
- 4Why the Houthis waited until now to strike
- 5The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- New movies to watch this weekend: See 'The Running Man' in theaters, rent 'One Battle After Another,' stream 'Nobody 2' on Peacock
- Turning into a Sharp Financial backer: Individual budget Wins
- Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
- Gartex Texprocess India to showcase innovations across textile ecosystem
- One killed, several injured in Iran missile barrage on southern, central Israel
- Must-See Attractions in Washington, D.C.
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- Putin critic gets six years in penal colony, vows hunger strike
- Why this Iranian island looks like Mars after it rains
